AUTHORS
Yan Gao, Xue-Ping Li2, Xuan-Ye Zhang3, Jicheng Hong4, Aiqiang Xia5, Huiqiang Huang, MD, PhD6
AFFILIATIONS
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Sun Yat-sen University Cancer Center, Guangzhou, China
3 Sun Yat-sen University Cancer Center, Guangzhou, China
4 Sun Yat-sen University Cancer Center, Guangzhou, China
5 Nanjing Geneseeq Technology Inc, Guangzhou, China
6 Sun Yat-sen University Cancer Center, Guangzhou, China
ABSTRACT
INTRODUCTION
Extranodal nasal-type NK/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma. Central nervous system (CNS) involvement is relatively rare (1.37%–16.70%) but portends rapid progression, high mortality, and extremely poor prognosis, with no standard therapy. Cerebrospinal fluid (CSF)-derived circulating tumor DNA (ctDNA) is a non-invasive biomarker enabling real-time molecular monitoring, yet its clinical value in CNS-involved ENKTL remains underexplored. We analyzed clinical characteristics, CSF ctDNA features, treatment strategies, and survival to inform diagnosis and individualized management.
METHODS
We retrospectively analyzed 54 patients with clinically recognized CNS involvement by ENKTL. CSF NGS at CNS involvement was available for 28 patients, including 27 with contemporaneous paired peripheral-blood NGS. CSF cytology, neuroimaging, and neurological symptoms were assessed per routine practice. NGS used a customized T-cell lymphoma-associated gene panel (mean depth >10,000×). Overall survival (OS) after CNS involvement was calculated from CNS diagnosis to death or last follow-up. Candidate CSF-enriched alterations were ranked by patient frequency; prognostic relevance of CIITA alterations was explored using Kaplan-Meier analysis.
RESULTS
Median age at CNS involvement was 49 years (IQR 37.5–53.0); 35 (64.8%) were male. CNS involvement was synchronous in 14 (25.9%) and metachronous in 40 (74.1%). Median diagnosis-to-CNS interval was 8.8 months (IQR 0.8–17.9). Among 54, 48.1% (26/54) had Ann Abort stage IV, 66.7% (39/54) ECOG PS >1, 70.4% (38/54) elevated LDH, 25.9% (14/54) hemophagocytic syndrome, and 81.5% (44/54) peripheral lesions. Median prior therapy lines were 2 (range 1–5). All 28 with CSF NGS had detectable mutations. Neurological symptoms, positive cytology, and positive imaging were present in 75.0% (21/28), 32.1% (9/28), and 21.4% (6/28), respectively. Sixteen patients (57.1%) had negative imaging and cytology but positive CSF NGS; 6 (21.4%) had no symptoms, imaging, or cytology but positive CSF NGS. Paired blood confirmed tumor-associated signals.
Median follow-up was 5.0 months (range 1–126.9); median OS for the entire cohort was 4.7 months (95% CI 3.2–6.4). After CNS involvement, 2 patients received no treatment; others received HD-MTX/temozolomide/thiotepa-based, gemcitabine/platinum/etoposide-containing, PD-1 inhibitor plus epigenetic, or novel (JAK1/XPO1 inhibitor) regimens. All 52 patients (100%) received intrathecal (IT) MTX/Ara-C/DXM (median 3, range 1–7); 5 (9.6%) received IT PD-1 inhibitor, 1 (1.9%) IT thiotepa. No OS difference was observed among regimens. Hemophagocytic syndrome patients had worse OS (3.8 vs 5.5 months, p=0.028).
Among 27 paired profiles, 308 CSF and 287 blood patient-variant events were detected; median mutation burden was 10 in each (p=0.660). Of 442 pooled events, 153 (34.6%) were shared, 155 (35.1%) CSF-specific, and 134 (30.3%) blood-specific. Median variant-level Jaccard similarity was 0.350 (IQR 0.250–0.495). CIITA and KMT2D were the most recurrent CSF-specific genes (each 4/27, 14.8%), followed by CDKN2A, FGFR2, FGFR4 (3 each, 11.1%). CIITA alterations included copy-number loss and frameshift/truncating variants (OncoKB deleterious). At CNS involvement, CIITA alterations were detected in 7/28 (6 CSF, 1 tissue). Median OS after CNS involvement was shorter in CIITA-altered than unaltered patients (3.3 vs 6.6 months; log-rank P=0.080).
CONCLUSIONS
CNS-involved ENKTL has a dismal prognosis and no optimal therapy, underscoring the need for novel agents. CSF ctDNA sequencing provides orthogonal molecular signals and identifies abnormalities in many patients without imaging or cytologic evidence. CIITA alterations show a non-significant trend toward shorter OS after CNS involvement. Their prognostic value and role in immune evasion require prospective validation.
DISCLOSURES
Huiqiang Huang, MD, PhD: No relevant conflicts of interest to declare.